Pfizer & Ranbaxy Kiss & Make Up on Lipitor & Caduet Patents
Pfizer (NYSE: PFE) and Ranbaxy Laboraories of India have settled their Lipitor patent litigation. The companies have entered into an agreement to settle substantially all of their patent litigation worldwide involving Lipitor.
Under the terms of the agreement, Ranbaxy will have a license to sell generic versions of Lipitor and Caduet in the United States effective November 30, 2011. The lawsuits between Pfizer and Ranbaxy over Lipitor and Caduet will be dismissed in the specified countries and Ranbaxy will drop its contesting of the validity of Pfizer’s patents in the specified countries. The agreement provides a license for Ranbaxy to sell generic versions of Lipitor on varying dates in seven additional countries on top of the U.S.: Canada, Belgium, Netherlands, Germany, Sweden, Italy and Australia.
The settlement will also resolve patent litigation with Ranbaxy over Accupril in the United States and Viagra in Ecuador.
The patent infringement litigation between Pfizer and Ranbaxy relating to Lipitor will continue in five other European countries: Finland, Spain, Portugal, Denmark and Romania.
Jon Ogg
June 18, 2008
Latest from 247Wallst.com- Latest from VSInvestor
- Top Day Trader Alerts (AIG, BPAX, C, DVN, ICO, TEAR)
- Top Day Trader Alerts (AEO, AIG, C, FACT, FNM, FRE, SOLR, ITMN)
- Russell 2000 Top Performers Since the Crash (ATSG, AXL, ARM, BZ, CKEC, CTIC, CNO, GPRE, HGSI, LZB, PIR, PWER, PMI, UIS, VNDA)
- Top Day Trader Alerts (CSCO, CNAM, NBG, FSLR, JSDA, DRYS, FEED, BWEN, FMD)
- DryShips… Rumors of a Rumor (DRYS)
